SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Essapen S.))
 

Sökning: (WFRF:(Essapen S.)) > 3 versus 6 months o...

  • Iveson, Timothy J.Southampton Univ Hosp NHS Fdn Trust, Southampton SO16 0YD, Hants, England (författare)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • ELSEVIER SCIENCE INC,2018
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-353105
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-353105URI
  • https://doi.org/10.1016/S1470-2045(18)30093-7DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment.Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1: 1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1.13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing.Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76.7% (95% CI 75.1-78.2) for the 3 month group and 77.1% (75.6-78.6) for the 6 month group, giving a hazard ratio of 1.006 (0.909-1.114, test for non-inferiority p=0.012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group).Interpretation: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kerr, Rachel S.Univ Oxford, Dept Oncol, Oxford, England (författare)
  • Saunders, Mark P.Christie Hosp, Manchester, Lancs, England (författare)
  • Cassidy, JimUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland (författare)
  • Henrik Hollander, NielsZealand Univ Hosp, Dept Oncol & Palliat Care, Naestved, Denmark (författare)
  • Tabernero, JosepVall dHebron Univ Hosp, Barcelona, Spain;Univ Autonoma Barcelona, CIBERONC, Inst Oncol, Barcelona, Spain (författare)
  • Haydon, AndrewAustralasian Gastrointestinal Trials Grp, Melbourne, Vic, Australia (författare)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (författare)
  • Harkin, AndreaUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland (författare)
  • Allan, KarenUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland (författare)
  • McQueen, JohnUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland (författare)
  • Scudder, ClaireUniv Oxford, Dept Oncol, OCTO, Oxford, England (författare)
  • Boyd, Kathleen AnneUniv Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland (författare)
  • Briggs, AndrewUniv Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland;Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Ctr Hlth & Policy Outcomes, New York, NY 10021 USA (författare)
  • Waterston, AshitaBeatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland (författare)
  • Medley, LouiseRoyal United Hosp, Bath, Avon, England (författare)
  • Wilson, CharlesAddenbrookes Hosp, Cambridge, England (författare)
  • Ellis, RichardRoyal Cornwall Hosp NHS Trust, Truro, England (författare)
  • Essapen, SharadahRoyal Surrey Cty Hosp NHS Fdn Trust, St Lukes Canc Ctr, Guildford, Surrey, England (författare)
  • Dhadda, Amandeep S.Castle Hill Hosp, Kingston Upon Hull, N Humberside, England (författare)
  • Harrison, MarkMt Vernon Canc Ctr, Northwood, Middx, England (författare)
  • Falk, StephenBristol Canc Inst, Bristol, Avon, England (författare)
  • Raouf, SherifBarking Havering & Redbridge Univ Hosp NHS Trust, Barking, England (författare)
  • Rees, CharlotteSouthampton Univ Hosp NHS Fdn Trust, Southampton SO16 0YD, Hants, England (författare)
  • Olesen, Rene K.Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark (författare)
  • Propper, DavidQueen Mary Univ London, Barts Canc Inst, London, England (författare)
  • Bridgewater, JohnUCL, UCL Canc Inst, London, England (författare)
  • Azzabi, AshrafNewcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle, England (författare)
  • Farrugia, DavidCheltenham Gen Hosp, Gloucestershire Oncol Ctr, Cheltenham, Glos, England (författare)
  • Webb, AndrewBrighton & Sussex Univ Hosp Trust, Brighton, E Sussex, England (författare)
  • Cunningham, DavidRoyal Marsden Hosp, London, England (författare)
  • Hickish, TamasBournemouth Univ, Poole Hosp, Bournemouth, Dorset, England (författare)
  • Weaver, AndrewOxford Univ Hosp Fdn Trust, Dept Oncol, Oxford, England (författare)
  • Gollins, SimonNorth Wales Canc Treatment Ctr, Rhyl, Wales (författare)
  • Wasan, Harpreet S.Imperial Coll London, Hammersmith Hosp, London, England (författare)
  • Paul, JamesUniv Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland (författare)
  • Southampton Univ Hosp NHS Fdn Trust, Southampton SO16 0YD, Hants, EnglandUniv Oxford, Dept Oncol, Oxford, England (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Lancet Oncology: ELSEVIER SCIENCE INC19:4, s. 562-5781470-20451474-5488

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy